表紙
市場調查報告書

肺癌診斷檢驗:醫療設備的開發平台評估

Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 408135
出版日期 內容資訊 英文 555 Pages
訂單完成後即時交付
價格
肺癌診斷檢驗:醫療設備的開發平台評估 Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年12月15日內容資訊: 英文 555 Pages
簡介

本報告提供全球肺癌診斷檢驗的相關市場上的主要開發中產品 (醫療設備) 及其臨床實驗的進展調查,再彙整產品特性比較分析 (臨床實驗的各進展階段) ,再加上主要企業簡介及代表性產品,近來的市場動靜 (資本交易·產業聯盟等) 等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 肺癌診斷檢驗概要

第3章 現在臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 現在進行中的臨床實驗

第4章 肺癌診斷檢驗:各企業現在臨床實驗中的開發中產品

  • 肺癌診斷檢驗的企業:各臨床實驗階段的開發中產品
  • 肺癌診斷檢驗:各臨床實驗階段的開發中產品

第5章 肺癌診斷檢驗的企業·產品概要

  • A&G Pharmaceutical Inc
  • Abbott Diagnostics
  • Abcodia Ltd
  • Aberystwyth University
  • Acobiom
  • Advanced Marker Discovery SL
  • Advpharma Inc
  • AIT Austrian Institute of Technology GmbH
  • Almac Diagnostics Ltd
  • Armune BioScience, Inc.
  • Aurelium BioPharma Inc.
  • Avant Diagnostics, Inc.
  • BioAffinity Technologies, Inc.
  • Biocept Inc
  • BioChain Institute Inc
  • Biodesix Inc
  • BioMark Diagnostics Inc.
  • BioMarker Strategies LLC
  • BioNTech AG
  • BioSystems International
  • BioTime Inc
  • Cangen Biotechnologies Inc
  • Cellanyx Diagnostics, Inc.
  • CellMax Life
  • CeMines, Inc.
  • Cepheid
  • Ceres Nanosciences Inc
  • Cernostics Inc.
  • ChemImage Corporation
  • Children's Hospital Boston
  • Clarient Inc
  • Courtagen Life Sciences Inc
  • DiagnoCure Inc. (Inactive)
  • EDP Biotech Corporation
  • Emory University
  • Epigenomics AG
  • Eventus Diagnostics Inc (Inactive)
  • Exact Sciences Corp
  • Exiqon A/S
  • Exosomics Siena SpA
  • Fahy Gurteen UK Ltd
  • Fina Biotech
  • Fluxion Biosciences, Inc.
  • Forschungszentrum Borstel
  • French National Institute of Health and Medical Research
  • Gene Express, Inc. (Inactive)
  • GeneCentric Diagnostics, Inc.
  • GenomicTree Inc
  • Global Discovery Biosciences Corporation
  • GlycoZym
  • HalioDx SAS
  • HTG Molecular Diagnostics Inc
  • ImmunoCellular Therapeutics Ltd
  • Inivata Ltd
  • Insight Genetics Inc
  • InterGenetics Inc
  • IV Diagnostics, Inc.
  • Janssen Biotech Inc
  • Laboratorios SALVAT SA
  • Louisville Bioscience, Inc.
  • Mayo Clinic US
  • MDNA Life Sciences Inc
  • MDxHealth SA
  • MEDITE Cancer Diagnostics Inc
  • Memory Dx LLC
  • Merrimack Pharmaceuticals Inc
  • Metabolon Inc
  • Metanomics Health GmbH
  • MetaStat Inc
  • Milagen, Inc.
  • Nanocytomics LLC
  • Nanopore Diagnostics, LLC
  • NEOMICS Co Ltd
  • Novel Bio-spectrum Technologies Inc
  • Nuvera Biosciences Inc
  • OncoCyte Corp
  • Oncolome Diagnostics Inc (Inactive)
  • Onconome, Inc. (Inactive)
  • OncoStem Diagnostics Pvt. Ltd
  • On-Q-ity, Inc. (Inactive)
  • OPKO Health Inc
  • Orion Genomics LLC
  • OTraces Inc.
  • Oxford Gene Technology Ltd
  • PeriRx LLC
  • PleX Diagnostics
  • Precision Biologics Inc
  • PreMD Inc
  • Proplex Technologies Llc
  • Proteome Sciences Plc
  • Proteomika
  • Provista Diagnostics Inc
  • Quest Diagnostics Inc
  • Roche Diagnostics International Ltd
  • Rosetta Genomics Ltd
  • Roswell Park Cancer Institute
  • Savicell Diagnostic Ltd.
  • Siemens Healthcare GmbH
  • Sienna Cancer Diagnostics Ltd
  • Simon Fraser University
  • Sividon Diagnostics GmbH
  • SomaLogic Inc
  • Southern Illinois University Carbondale
  • Syndax Pharmaceuticals Inc
  • The Wistar Institute
  • Todos Medical
  • Transgene SA
  • Trinity College Dublin
  • Universal Diagnostics, S. L.
  • University of California San Francisco
  • University of Chicago
  • University of Colorado
  • University of South Florida
  • University of Strathclyde
  • US Biomarkers Inc
  • Vanderbilt University
  • Ventana Medical Systems Inc
  • Vigilant Biosciences, Inc.
  • Viomics Inc.
  • VisionGate, Inc.
  • Vitatex Inc.
  • VolitionRX Ltd
  • Weizmann Institute of Science
  • XEPTAGEN SpA
  • Zetiq Technologies Ltd

第6章 肺癌診斷檢驗市場:目前的趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0839EPD

GlobalData's Medical Devices sector report, "Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Lung Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Lung Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Lung Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Lung Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1 List of Tables 15
  • 1.2 List of Figures 24

2 Introduction 25

  • 2.1 Lung Cancer Diagnostic Tests Overview 25

3 Products under Development 26

  • 3.1 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 26
  • 3.2 Lung Cancer Diagnostic Tests - Pipeline Products by Territory 27
  • 3.3 Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 28
  • 3.4 Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 29
  • 3.5 Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 30

4 Lung Cancer Diagnostic Tests - Pipeline Products under Development by Companies 31

  • 4.1 Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 31
  • 4.2 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 36

5 Lung Cancer Diagnostic Tests Companies and Product Overview 41

6 Lung Cancer Diagnostic Tests - Recent Developments 220

7 Appendix 540

List of Tables

  • Table 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 26
  • Table 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 27
  • Table 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 28
  • Table 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 29
  • Table 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 30
  • Table 6: Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 31
  • Table 7: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 36
  • Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 9: Onco 88 - Lung Cancer Diagnostic Tests - Product Status 41
  • Table 10: Onco 88 - Lung Cancer Diagnostic Tests - Product Description 41
  • Table 11: OncoStain 88 - Lung Cancer Diagnostic Tests - Product Status 42
  • Table 12: OncoStain 88 - Lung Cancer Diagnostic Tests - Product Description 42
  • Table 13: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 14: ARCHITECT c4000 System - NSE Assay - Product Status 43
  • Table 15: ARCHITECT c4000 System - NSE Assay - Product Description 44
  • Table 16: ARCHITECT c8000 System - NSE Assay - Product Status 44
  • Table 17: ARCHITECT c8000 System - NSE Assay - Product Description 44
  • Table 18: ARCHITECT ci4100 Integrated System - NSE Assay - Product Status 45
  • Table 19: ARCHITECT ci4100 Integrated System - NSE Assay - Product Description 45
  • Table 20: ARCHITECT ci8200 Integrated System - NSE Assay - Product Status 45
  • Table 21: ARCHITECT ci8200 Integrated System - NSE Assay - Product Description 46
  • Table 22: ARCHITECT i1000SR System - NSE Assay - Product Status 46
  • Table 23: ARCHITECT i1000SR System - NSE Assay - Product Description 46
  • Table 24: ARCHITECT i2000SR Integrated System - Neuron-Specific Enolase Assay - Product Status 47
  • Table 25: ARCHITECT i2000SR Integrated System - Neuron-Specific Enolase Assay - Product Description 47
  • Table 26: PRAME Antigen Lung Cancer Assay - Product Status 47
  • Table 27: PRAME Antigen Lung Cancer Assay - Product Description 48
  • Table 28: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 29: Diagnostic Assay - Lung Cancer Diagnostic Tests - Product Status 49
  • Table 30: Diagnostic Assay - Lung Cancer Diagnostic Tests - Product Description 49
  • Table 31: MCM Test - Lung Cancer Diagnostic Tests - Product Status 50
  • Table 32: MCM Test - Lung Cancer Diagnostic Tests - Product Description 50
  • Table 33: Aberystwyth University Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 34: Diagnostic Biomarker Test - Lung Cancer Diagnostic Tests - Product Status 51
  • Table 35: Diagnostic Biomarker Test - Lung Cancer Diagnostic Tests - Product Description 51
  • Table 36: Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 37: Diagnostic Test - ACTN4 - Product Status 52
  • Table 38: Diagnostic Test - ACTN4 - Product Description 53
  • Table 39: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 40: Companion Diagnostic Test - Lung Cancer Diagnostic Tests - Product Status 54
  • Table 41: Companion Diagnostic Test - Lung Cancer Diagnostic Tests - Product Description 54
  • Table 42: Diagnostic/Prognostic Assay - Lung Cancer Diagnostic Tests - Product Status 55
  • Table 43: Diagnostic/Prognostic Assay - Lung Cancer Diagnostic Tests - Product Description 55
  • Table 44: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 45: DiagnoLung - Product Status 56
  • Table 46: DiagnoLung - Product Description 56
  • Table 47: Predictive Diagnostic Test - Lung Cancer Diagnostic Tests - Product Status 57
  • Table 48: Predictive Diagnostic Test - Lung Cancer Diagnostic Tests - Product Description 57
  • Table 49: Prognostic Test - Lung Cancer Diagnostic Tests - Product Status 57
  • Table 50: Prognostic Test - Lung Cancer Diagnostic Tests - Product Description 58
  • Table 51: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 52: Biomarker Assay - Lung Cancer Diagnostic Tests - Product Status 59
  • Table 53: Biomarker Assay - Lung Cancer Diagnostic Tests - Product Description 59
  • Table 54: Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 55: Prognostic Test - Early Stage Lung Cancer Diagnostic Tests - Product Status 60
  • Table 56: Prognostic Test - Early Stage Lung Cancer Diagnostic Tests - Product Description 60
  • Table 57: Prognostic Test - NSCLC - Product Status 61
  • Table 58: Prognostic Test - NSCLC - Product Description 61
  • Table 59: ANGLE plc Pipeline Products & Ongoing Clinical Trials Overview 62

List of Figures

  • Figure 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 26
  • Figure 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 27
  • Figure 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 28
  • Figure 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 29
  • Figure 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 30